BLUE - bluebird bio Stock Price, News & Analysis

$167.20 -0.05 (-0.03 %)
(As of 11/24/2017 04:03 AM ET)
Previous Close$167.25
Today's Range$165.25 - $169.10
52-Week Range$56.80 - $169.60
Volume363,700 shs
Average Volume835,569 shs
Market Capitalization$7.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.02

About bluebird bio (NASDAQ:BLUE)

bluebird bio logobluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLUE
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio9.88%
Quick Ratio9.88%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.16 million
Price / Sales1,243.96
Cash FlowN/A
Price / CashN/A
Book Value$24.90 per share
Price / Book6.71

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($7.02)
Net Income$-263,500,000.00
Net Margins-883.18%
Return on Equity-28.79%
Return on Assets-22.94%

Miscellaneous

Employees328
Outstanding Shares45,830,000

Frequently Asked Questions for bluebird bio (NASDAQ:BLUE)

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) released its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing analysts' consensus estimates of ($1.68) by $0.05. The biotechnology company had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The firm's revenue for the quarter was up 397.4% on a year-over-year basis. During the same period in the previous year, the business earned ($2.07) earnings per share. View bluebird bio's Earnings History.

When will bluebird bio make its next earnings announcement?

bluebird bio is scheduled to release their next quarterly earnings announcement on Tuesday, February, 20th 2018. View Earnings Estimates for bluebird bio.

Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2017?

21 brokers have issued 12 month price targets for bluebird bio's shares. Their forecasts range from $58.00 to $186.00. On average, they anticipate bluebird bio's stock price to reach $131.70 in the next twelve months. View Analyst Ratings for bluebird bio.

What are Wall Street analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:

  • 1. Cantor Fitzgerald analysts commented, "Directionally Improving. From the ASH abstracts we have an early glimpse at the modified drug manufacturing process for SCD. Two patients were treated with the modified drug product having VCNs of 1.4/3.3 and 5.0/2.9, respectively. In patient 1313, VCN dropped in peripheral blood to 0.5 and HbA T87Q was measured at 1.5g/dL by three months. Patient 1312 demonstrated a declining VCN at 2.6 at one month. While the first patient demonstrated HbA T87Q of 1.5g/dL, we note that these concentrations may not reach steady state until nine months following drug product infusion. While an additional eight patients treated with apheresis-derived (previously bone marrow) stem cells have been enrolled by July 21, 2017, we do not expect in vivo clinical data at ASH. bluebird expects to provide an update on its fully enrolled (n=15) Northstar-2 trial in b-thalassemia patients with the non-b0/b0 genotype at ASH." (11/1/2017)
  • 2. Morgan Stanley analysts commented, "excitement." But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm's Matthew Harrison downgraded Bluebird's stock rating from Equal Weight to Underweight with an unchanged $105 price target.Heading into the end of 2017 there are underappreciated risks that the Street may be ignoring, Harrison commented. Specifically, data related to LentiGlobin sickle cell data is unlikely to show any significant improvement in hemoglobin production that will be good enough to "increase investor confidence" in its sickle cell gene therapy."Based on prior data, our premise is that to improve hemoglobin production in sickle cell patients, the correlation between drug-product vector copy number (DP VCN) and peripheral VCN (pVCN) needs to increase substantially," the analyst explained. "We do not believe the evidence supports current investor optimism that this can be solved by ASH." (10/2/2017)
  • 3. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (7/18/2017)
  • 4. BTIG Research analysts commented, "generally captured" data updates from ASCO and EHA. Positive On Outlook But Not Enough To Remain BullishMeanwhile, Bluebird has a "good lead" over the competition in drugs targeting anti-BCMA and a Phase 1 study of bb21217 will commence in the bottom half of 2017. But at the same time competitive efforts from rivals will also ramp up, including Kite Pharma Inc (NASDAQ: KITE), which will begin a study of a fully-human anti-BCMA CAR T therapy in the third quarter.The analyst remains "more optimistic than most" regarding the LentiGlobin program for Beta-thalassemia and Sickle-cell disease. Also, the company's broadening of its oncology efforts may be a source of concern among some investors but early success in bb2121 is indeed supportive of a "broader effort in larger markets with better defined patient populations." (6/30/2017)
  • 5. Maxim Group analysts commented, "bluebird announced updated data at the ongoing ASCO (American Society of Clinical Oncology) meeting for bb2121 CAR-T in the CRB-401 Phase 1 study targeting relapsed/refractory multiple myeloma (r/r/ MM)." (6/2/2017)

Who are some of bluebird bio's key competitors?

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:

  • Daniel S. Lynch, Independent Chairman of the Board (Age 59)
  • Nick Leschly, President, Chief Executive Officer, Director (Age 44)
  • Jeffrey T. Walsh, Chief Financial and Strategy Officer and Principal Financial Officer, Principal Accounting Officer (Age 51)
  • Susanna Gatti High, Chief Operating Officer (Age 49)
  • Philip D. Gregory Ph.D., Chief Scientific Officer (Age 46)
  • David M. Davidson M.D., Chief Medical Officer (Age 53)
  • Jason F. Cole Esq., Chief Legal Officer, Secretary (Age 44)
  • John O. Agwunobi M.D., Director (Age 52)
  • Mary Lynne Hedley Ph.D., Director (Age 54)
  • Douglas A. Melton, Director

Who owns bluebird bio stock?

bluebird bio's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (11.67%), Victory Capital Management Inc. (1.66%), Jennison Associates LLC (1.45%), Orbimed Advisors LLC (1.05%), Ameriprise Financial Inc. (0.74%) and Schwab Charles Investment Management Inc. (0.58%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly and Philip D Gregory. View Institutional Ownership Trends for bluebird bio.

Who sold bluebird bio stock? Who is selling bluebird bio stock?

bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Jennison Associates LLC, Baillie Gifford & Co., Pictet Asset Management Ltd., Wells Fargo & Company MN, Candriam Luxembourg S.C.A., New York State Common Retirement Fund and Emerald Advisers Inc. PA. Company insiders that have sold bluebird bio company stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly and Philip D Gregory. View Insider Buying and Selling for bluebird bio.

Who bought bluebird bio stock? Who is buying bluebird bio stock?

bluebird bio's stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., American Century Companies Inc., Schwab Charles Investment Management Inc., Frontier Capital Management Co. LLC, Orbimed Advisors LLC, Columbus Circle Investors, Dimensional Fund Advisors LP and Mitsubishi UFJ Trust & Banking Corp. View Insider Buying and Selling for bluebird bio.

How do I buy bluebird bio stock?

Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of bluebird bio stock can currently be purchased for approximately $167.20.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $7.66 billion and generates $6.16 million in revenue each year. The biotechnology company earns $-263,500,000.00 in net income (profit) each year or ($7.02) on an earnings per share basis. bluebird bio employs 328 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]


MarketBeat Community Rating for bluebird bio (BLUE)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  620 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  854
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for bluebird bio (NASDAQ:BLUE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 5 Hold Ratings, 14 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $131.70 (21.23% downside)

Consensus Price Target History for bluebird bio (NASDAQ:BLUE)

Price Target History for bluebird bio (NASDAQ:BLUE)

Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017Maxim GroupSet Price TargetBuy$170.00N/AView Rating Details
11/3/2017SunTrust Banks, Inc.Boost Price TargetBuy -> Buy$108.00 -> $163.00N/AView Rating Details
11/3/2017Jefferies Group LLCReiterated RatingHold$130.00N/AView Rating Details
11/3/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
11/2/2017Barclays PLCBoost Price TargetOverweight$151.00 -> $162.00N/AView Rating Details
11/2/2017WedbushReiterated RatingOutperform$135.00 -> $174.00N/AView Rating Details
11/2/2017BTIG ResearchUpgradeNeutral -> Buy$177.00N/AView Rating Details
11/1/2017Leerink SwannReiterated RatingOutperform$145.00 -> $162.00N/AView Rating Details
11/1/2017Cantor FitzgeraldReiterated RatingSell$39.00 -> $58.00N/AView Rating Details
10/30/2017BMO Capital MarketsBoost Price TargetBuy$134.00 -> $162.00N/AView Rating Details
10/16/2017Evercore ISIUpgradeIn-Line -> Outperform$102.00N/AView Rating Details
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy -> Buy$186.00N/AView Rating Details
9/5/2017Wells Fargo & CoReiterated RatingOutperform -> Outperform$134.00 -> $158.00MediumView Rating Details
8/31/2017Cowen IncReiterated RatingOutperformHighView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$109.00HighView Rating Details
6/26/2017Janney Montgomery ScottSet Price TargetBuy$125.00N/AView Rating Details
6/16/2017Standpoint ResearchReiterated RatingBuy -> Reduce$110.00LowView Rating Details
6/5/2017Bank of America CorporationReiterated RatingHold$95.00HighView Rating Details
2/23/2017Roth CapitalSet Price TargetHold$71.00N/AView Rating Details
12/7/2016J P Morgan Chase & CoReiterated RatingBuy$120.00N/AView Rating Details
11/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for bluebird bio (NASDAQ:BLUE)

Earnings by Quarter for bluebird bio (NASDAQ:BLUE)

Earnings History by Quarter for bluebird bio (NASDAQ BLUE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018($1.68)N/AView Earnings Details
11/1/2017Q3 2017($1.68)($1.73)$8.47 million$7.71 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.66)($1.73)$6.29 million$16.70 millionViewN/AView Earnings Details
5/3/2017Q1 2017($1.76)($1.68)$1.51 million$6.83 millionViewN/AView Earnings Details
2/22/2017Q4 2016($1.86)($1.88)$1.76 million$1.55 millionViewN/AView Earnings Details
11/2/2016Q3 2016($1.59)($2.07)$1.82 million$1.55 millionViewN/AView Earnings Details
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
11/4/2015Q3($0.96)($1.18)$5.63 million$1.30 millionViewListenView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.68)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.62)($0.66)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.52)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)ViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for bluebird bio (NASDAQ:BLUE)
2017 EPS Consensus Estimate: ($7.19)
2018 EPS Consensus Estimate: ($6.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($1.88)($1.79)($1.83)
Q2 20175($1.89)($1.60)($1.75)
Q3 20175($1.94)($1.73)($1.80)
Q4 20175($2.03)($1.71)($1.81)
Q1 20181($1.68)($1.68)($1.68)
Q2 20181($1.66)($1.66)($1.66)
Q3 20181($1.73)($1.73)($1.73)
Q4 20181($1.76)($1.76)($1.76)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for bluebird bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for bluebird bio (NASDAQ BLUE)

Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)
Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Insider Trades by Quarter for bluebird bio (NASDAQ BLUE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2017Jeffrey T WalshInsiderSell9,900$149.58$1,480,842.00View SEC Filing  
11/1/2017Jeffrey T WalshInsiderSell35,000$151.38$5,298,300.00View SEC Filing  
11/1/2017Nick LeschlyCEOSell2,127$145.17$308,776.59View SEC Filing  
10/23/2017Nick LeschlyInsiderSell7,050$145.14$1,023,237.00View SEC Filing  
10/20/2017Nick LeschlyCEOSell3,350$145.02$485,817.00View SEC Filing  
10/17/2017Nick LeschlyCEOSell10,823$145.05$1,569,876.15View SEC Filing  
10/10/2017Jeffrey T WalshInsiderSell4,900$129.94$636,706.00View SEC Filing  
10/2/2017David DavidsonInsiderSell4,000$131.31$525,240.00View SEC Filing  
9/14/2017John MaraganoreDirectorSell18,868$131.21$2,475,670.28View SEC Filing  
9/12/2017Mark VachonDirectorSell6,000$126.82$760,920.00View SEC Filing  
9/11/2017Jeffrey T WalshInsiderSell4,900$125.73$616,077.00View SEC Filing  
9/1/2017Nick LeschlyInsiderSell46,833$122.27$5,726,270.91View SEC Filing  
8/31/2017Daniel LynchDirectorSell500$120.00$60,000.00View SEC Filing  
8/31/2017Jeffrey T WalshInsiderSell12,000$125.01$1,500,120.00View SEC Filing  
8/30/2017Nick LeschlyInsiderSell25,667$115.18$2,956,325.06View SEC Filing  
8/28/2017Jeffrey T WalshInsiderSell1,250$107.06$133,825.00View SEC Filing  
8/14/2017James MandellDirectorSell1,000$95.95$95,950.00View SEC Filing  
8/10/2017Jeffrey T WalshInsiderSell1,250$95.41$119,262.50View SEC Filing  
8/7/2017Philip D GregoryInsiderSell750$99.00$74,250.00View SEC Filing  
8/4/2017Eric SullivanInsiderSell861$93.83$80,787.63View SEC Filing  
8/1/2017David DavidsonInsiderSell3,000$92.37$277,110.00View SEC Filing  
7/10/2017Jeffrey T WalshInsiderSell2,500$99.89$249,725.00View SEC Filing  
7/7/2017David DavidsonInsiderSell1,200$100.49$120,588.00View SEC Filing  
7/6/2017Philip D GregoryInsiderSell2,250$103.83$233,617.50View SEC Filing  
7/5/2017David DavidsonInsiderSell5,000$105.28$526,400.00View SEC Filing  
6/29/2017Eric SullivanInsiderSell6,787$108.96$739,511.52View SEC Filing  
6/27/2017Nick LeschlyInsiderSell25,000$108.05$2,701,250.00View SEC Filing  
6/23/2017Daniel LynchDirectorSell4,000$109.09$436,360.00View SEC Filing  
6/20/2017Daniel LynchDirectorSell2,500$120.03$300,075.00View SEC Filing  
6/7/2017Jason ColeInsiderSell17,245$100.22$1,728,293.90View SEC Filing  
6/6/2017Daniel LynchDirectorSell2,263$100.14$226,616.82View SEC Filing  
6/6/2017Philip D GregoryInsiderSell1,500$99.04$148,560.00View SEC Filing  
6/5/2017David DavidsonInsiderSell1,000$90.00$90,000.00View SEC Filing  
5/25/2017Daniel LynchDirectorSell2,000$80.00$160,000.00View SEC Filing  
4/27/2017Daniel LynchDirectorSell1,000$90.01$90,010.00View SEC Filing  
4/25/2017Daniel LynchDirectorSell2,000$86.75$173,500.00View SEC Filing  
4/10/2017Jeffrey T WalshInsiderSell1,250$87.38$109,225.00View SEC Filing  
4/3/2017David DavidsonInsiderSell3,000$90.89$272,670.00View SEC Filing  
3/27/2017Daniel LynchDirectorSell3,000$88.12$264,360.00View SEC Filing  
3/16/2017Daniel LynchDirectorSell237$100.07$23,716.59View SEC Filing  
3/16/2017Jason ColeInsiderSell4,930$100.07$493,345.10View SEC Filing  
3/3/2017John MaraganoreDirectorSell13,839$85.02$1,176,591.78View SEC Filing  
2/15/2017Daniel LynchDirectorSell150$80.22$12,033.00View SEC Filing  
2/15/2017Jason ColeInsiderSell666$80.22$53,426.52View SEC Filing  
2/14/2017Daniel LynchDirectorSell850$80.01$68,008.50View SEC Filing  
2/14/2017Jason ColeInsiderSell3,772$80.01$301,797.72View SEC Filing  
1/31/2017James MandellDirectorSell8,000$75.04$600,320.00View SEC Filing  
1/27/2017Daniel LynchDirectorSell1,000$70.09$70,090.00View SEC Filing  
1/27/2017David DavidsonInsiderSell6,000$69.02$414,120.00View SEC Filing  
1/5/2017Jason ColeInsiderSell549$67.10$36,837.90View SEC Filing  
10/3/2016Eric SullivanInsiderSell416$67.00$27,872.00View SEC Filing  
9/13/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.12View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.28View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.00View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.12View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.00View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.00View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.00View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.00View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.00View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for bluebird bio (NASDAQ BLUE)

Source:
DateHeadline
bluebird bio, Inc. (BLUE) Expected to Announce Quarterly Sales of $7.58 Millionbluebird bio, Inc. (BLUE) Expected to Announce Quarterly Sales of $7.58 Million
www.americanbankingnews.com - November 24 at 2:36 AM
bluebird bio, Inc. (BLUE) Expected to Announce Earnings of -$1.59 Per Sharebluebird bio, Inc. (BLUE) Expected to Announce Earnings of -$1.59 Per Share
www.americanbankingnews.com - November 22 at 11:10 PM
Maxim Group Analysts Give bluebird bio, Inc. (BLUE) a $170.00 Price TargetMaxim Group Analysts Give bluebird bio, Inc. (BLUE) a $170.00 Price Target
www.americanbankingnews.com - November 18 at 8:48 AM
Celgene CAR-T Therapy Gets Breakthrough Therapy DesignationCelgene CAR-T Therapy Gets Breakthrough Therapy Designation
www.nasdaq.com - November 17 at 7:47 PM
bluebird bio (BLUE) Says First Patient Treated in Northstar-3, Phase 3 Study of LentiGlobin in Patients with TDTbluebird bio (BLUE) Says First Patient Treated in Northstar-3, Phase 3 Study of LentiGlobin in Patients with TDT
www.streetinsider.com - November 17 at 7:47 PM
ETFs with exposure to bluebird bio, Inc. : November 16, 2017ETFs with exposure to bluebird bio, Inc. : November 16, 2017
finance.yahoo.com - November 17 at 7:47 PM
bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients ... - Business Wire (press release)bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients ... - Business Wire (press release)
www.businesswire.com - November 16 at 12:04 PM
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted ... - Business Wire (press release)Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted ... - Business Wire (press release)
www.businesswire.com - November 16 at 12:04 PM
bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotypebluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype
finance.yahoo.com - November 16 at 12:04 PM
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple MyelomaCelgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma
finance.yahoo.com - November 16 at 12:04 PM
ETFs with exposure to bluebird bio, Inc. : November 16, 2017ETFs with exposure to bluebird bio, Inc. : November 16, 2017
finance.yahoo.com - November 16 at 12:04 PM
Insider Selling: bluebird bio, Inc. (BLUE) Insider Sells 9,900 Shares of StockInsider Selling: bluebird bio, Inc. (BLUE) Insider Sells 9,900 Shares of Stock
www.americanbankingnews.com - November 14 at 4:32 PM
Head-To-Head Analysis: Ardelyx (ARDX) vs. bluebird bio (BLUE)Head-To-Head Analysis: Ardelyx (ARDX) vs. bluebird bio (BLUE)
www.americanbankingnews.com - November 10 at 9:10 PM
Cantor Fitzgerald Weighs in on bluebird bio, Inc.s FY2017 Earnings (BLUE)Cantor Fitzgerald Weighs in on bluebird bio, Inc.'s FY2017 Earnings (BLUE)
www.americanbankingnews.com - November 8 at 12:30 PM
ETFs with exposure to bluebird bio, Inc. : November 6, 2017ETFs with exposure to bluebird bio, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 5:43 PM
Jefferies Group Research Analysts Raise Earnings Estimates for bluebird bio, Inc. (BLUE)Jefferies Group Research Analysts Raise Earnings Estimates for bluebird bio, Inc. (BLUE)
www.americanbankingnews.com - November 6 at 7:14 AM
FY2017 EPS Estimates for bluebird bio, Inc. Boosted by Analyst (BLUE)FY2017 EPS Estimates for bluebird bio, Inc. Boosted by Analyst (BLUE)
www.americanbankingnews.com - November 6 at 7:14 AM
FY2017 Earnings Forecast for bluebird bio, Inc. Issued By Leerink Swann (BLUE)FY2017 Earnings Forecast for bluebird bio, Inc. Issued By Leerink Swann (BLUE)
www.americanbankingnews.com - November 6 at 7:14 AM
bluebird bio, Inc. (BLUE) Raised to "Equal Weight" at Morgan Stanleybluebird bio, Inc. (BLUE) Raised to "Equal Weight" at Morgan Stanley
www.americanbankingnews.com - November 5 at 6:58 PM
bluebird bio, Inc. (BLUE) Receives Hold Rating from Jefferies Group LLCbluebird bio, Inc. (BLUE) Receives Hold Rating from Jefferies Group LLC
www.americanbankingnews.com - November 5 at 4:56 PM
bluebird bio, Inc. (BLUE) Price Target Raised to $163.00bluebird bio, Inc. (BLUE) Price Target Raised to $163.00
www.americanbankingnews.com - November 5 at 11:46 AM
bluebird bio, Inc. (BLUE) CEO Sells $308,776.59 in Stockbluebird bio, Inc. (BLUE) CEO Sells $308,776.59 in Stock
www.americanbankingnews.com - November 3 at 5:42 PM
bluebird bio, Inc. (BLUE) Insider Jeffrey T. Walsh Sells 35,000 Sharesbluebird bio, Inc. (BLUE) Insider Jeffrey T. Walsh Sells 35,000 Shares
www.americanbankingnews.com - November 3 at 5:24 PM
bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 5:13 PM
Here's Why bluebird bio Inc. Is Surging Again TodayHere's Why bluebird bio Inc. Is Surging Again Today
finance.yahoo.com - November 2 at 10:15 PM
bluebird bio, Inc. (BLUE) Forecasted to Post FY2021 Earnings of $4.38 Per Sharebluebird bio, Inc. (BLUE) Forecasted to Post FY2021 Earnings of $4.38 Per Share
www.americanbankingnews.com - November 2 at 5:34 PM
Todays Research Reports on Stocks to Watch: Momenta Pharmaceuticals and bluebird bioToday's Research Reports on Stocks to Watch: Momenta Pharmaceuticals and bluebird bio
finance.yahoo.com - November 2 at 5:13 PM
bluebird bio, Inc. (BLUE) Releases Quarterly  Earnings Results, Misses Estimates By $0.05 EPSbluebird bio, Inc. (BLUE) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - November 2 at 3:07 PM
bluebird bio, Inc. (BLUE) Receives Consensus Rating of "Hold" from Analystsbluebird bio, Inc. (BLUE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 2 at 2:10 PM
Bluebird Bio Inc. (BLUE) Has Surged To A New High After Q3 ReportBluebird Bio Inc. (BLUE) Has Surged To A New High After Q3 Report
www.nasdaq.com - November 1 at 10:19 PM
bluebird bio, Inc. 2017 Q3 - Results - Earnings Call Slidesbluebird bio, Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 1 at 10:19 PM
bluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed/Refractory Multiple Myeloma at ASH Annual Meetingbluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
finance.yahoo.com - November 1 at 10:19 PM
bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progressbluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress
finance.yahoo.com - November 1 at 10:19 PM
Bluebird reports 3Q lossBluebird reports 3Q loss
finance.yahoo.com - November 1 at 10:19 PM
How Blood-Disease Data Sent These 2 Biotech Stocks FlyingHow Blood-Disease Data Sent These 2 Biotech Stocks Flying
finance.yahoo.com - November 1 at 10:19 PM
Edited Transcript of BLUE earnings conference call or presentation 1-Nov-17 12:30pm GMTEdited Transcript of BLUE earnings conference call or presentation 1-Nov-17 12:30pm GMT
finance.yahoo.com - November 1 at 10:19 PM
Leerink Swann Reiterates Outperform Rating for bluebird bio, Inc. (BLUE)Leerink Swann Reiterates Outperform Rating for bluebird bio, Inc. (BLUE)
www.americanbankingnews.com - November 1 at 7:08 PM
Bluebird Bio Sharply Higher After Mixed Q3 Report - BenzingaBluebird Bio Sharply Higher After Mixed Q3 Report - Benzinga
www.benzinga.com - November 1 at 5:18 PM
Why bluebird bio Inc. Jumped Higher Today - Motley FoolWhy bluebird bio Inc. Jumped Higher Today - Motley Fool
www.fool.com - November 1 at 5:18 PM
bluebird bio, Inc. (BLUE) Given "Sell" Rating at Cantor Fitzgeraldbluebird bio, Inc. (BLUE) Given "Sell" Rating at Cantor Fitzgerald
www.americanbankingnews.com - November 1 at 2:40 PM
bluebird bio Announces ASH Abstract Conference Call on November 1st and Upcoming Investor Events in Novemberbluebird bio Announces ASH Abstract Conference Call on November 1st and Upcoming Investor Events in November
finance.yahoo.com - October 31 at 5:46 PM
Why Earnings Season Could Be Great for bluebird bio (BLUE)Why Earnings Season Could Be Great for bluebird bio (BLUE)
www.nasdaq.com - October 30 at 5:42 PM
bluebird bio, Inc. (BLUE) CEO Nick Leschly Sells 3,350 Sharesbluebird bio, Inc. (BLUE) CEO Nick Leschly Sells 3,350 Shares
www.americanbankingnews.com - October 24 at 10:33 PM
Nick Leschly Sells 7,050 Shares of bluebird bio, Inc. (BLUE) StockNick Leschly Sells 7,050 Shares of bluebird bio, Inc. (BLUE) Stock
www.americanbankingnews.com - October 24 at 7:18 PM
bluebird bio, Inc. (BLUE) Scheduled to Post Earnings on Tuesdaybluebird bio, Inc. (BLUE) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 24 at 9:58 AM
Commit To Buy bluebird bio At $85, Earn 15.1% Using OptionsCommit To Buy bluebird bio At $85, Earn 15.1% Using Options
www.nasdaq.com - October 23 at 5:33 PM
Nick Leschly Sells 10,823 Shares of bluebird bio, Inc. (BLUE) StockNick Leschly Sells 10,823 Shares of bluebird bio, Inc. (BLUE) Stock
www.americanbankingnews.com - October 19 at 4:36 PM
bluebird bio, Inc. (BLUE) Expected to Post Quarterly Sales of $8.98 Millionbluebird bio, Inc. (BLUE) Expected to Post Quarterly Sales of $8.98 Million
www.americanbankingnews.com - October 17 at 9:23 AM
The BLUE And The BOLD; Analyst Suggests Pair Trade Ahead Of Year-End Catalysts - BenzingaThe BLUE And The BOLD; Analyst Suggests Pair Trade Ahead Of Year-End Catalysts - Benzinga
www.benzinga.com - October 16 at 10:24 PM
Jefferies Group Comments on bluebird bio, Inc.s Q3 2017 Earnings (BLUE)Jefferies Group Comments on bluebird bio, Inc.'s Q3 2017 Earnings (BLUE)
www.americanbankingnews.com - October 13 at 6:46 AM

Social Media

Financials

Chart

bluebird bio (NASDAQ BLUE) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.